| 2.11 0 (0%) | 08-19 12:15 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.97 | 1-year : | 3.49 |
| Resists | First : | 2.54 | Second : | 2.99 |
| Pivot price | 2.19 |
|||
| Supports | First : | 1.82 | Second : | 1.51 |
| MAs | MA(5) : | 2.09 |
MA(20) : | 2.15 |
| MA(100) : | 3.33 |
MA(250) : | 5.46 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.8 |
D(3) : | 13.6 |
| RSI | RSI(14): 38.8 |
|||
| 52-week | High : | 12.8 | Low : | 1.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BHST ] has closed above bottom band by 28.0%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.3 - 2.31 | 2.31 - 2.33 |
| Low: | 2.08 - 2.1 | 2.1 - 2.11 |
| Close: | 2.09 - 2.11 | 2.11 - 2.13 |
BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.
Tue, 18 Aug 2026
symbol__ Stock Quote Price and Forecast - cnn.com
Fri, 14 Aug 2026
BioHarvest Sciences Inc. Common Stock (NASDAQ: BHST) Stock Price, News & Analysis - Kalkine
Tue, 11 Aug 2026
What Could BioHarvest Sciences (NASDAQ:BHST) Quarterly Update Show? - Kalkine Media
Tue, 11 Aug 2026
BioHarvest revenue rises 3.8% to $8.8 million - grafa.com
Thu, 14 May 2026
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Fri, 03 Apr 2026
What Does BioHarvest Sciences Inc.'s (NASDAQ:BHST) Share Price Indicate? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Basic Materials
|
|
|
Industry:
Agricultural Inputs
|
|
| Shares Out | 23 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 14.7 (%) |
| Held by Institutions | 7.9 (%) |
| Shares Short | 72 (K) |
| Shares Short P.Month | 67 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.01 |
| Profit Margin | -32.6 % |
| Operating Margin | -21.6 % |
| Return on Assets (ttm) | -9.9 % |
| Return on Equity (ttm) | -103.3 % |
| Qtrly Rev. Growth | 8.1 % |
| Gross Profit (p.s.) | 0.92 |
| Sales Per Share | 1.55 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -3.56 |
| PEG Ratio | 0 |
| Price to Book value | 2.01 |
| Price to Sales | 1.32 |
| Price to Cash Flow | -6.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|